<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574377</url>
  </required_header>
  <id_info>
    <org_study_id>NL49528.000.14</org_study_id>
    <nct_id>NCT02574377</nct_id>
  </id_info>
  <brief_title>myDC/pDC in Stage III Melanoma Patients</brief_title>
  <official_title>Myeloid and Plasmacytoid Blood Dendritic Cells for Immunotherapy of Stage III Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      This is an interventional study to test the immunogenicity of combined adjuvant myDC and pDC
      vaccination versus adjuvant myDC or pDC vaccination alone in stage III melanoma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stage lll melanoma patients will receive pDC (arm A, n=10), myDC (arm B, n=10) or combined
      pDC/myDC (arm C, n=10). Subsequent vaccinations will be performed according to the protocol:
      2 biweekly vaccinations of intranodal injections with pDC, myDC or the combination with pDC
      and myDC. After each vaccination the investigators will examine peripheral blood for
      proliferative and humoral KLH immune responses. After the vaccinations, a DTH with peptide
      loaded blood DC is performed from which biopsies are taken for T cell analysis. lf patients
      remain disease free, the investigators will repeat this cycle with a 6 months interval up to
      a total of three cycles. lf a tumor recurrence occurs a biopsy will be taken for laboratory
      evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>immunogenicity - type I IFN</measure>
    <time_frame>up to 1.5 years</time_frame>
    <description>Type I IFN gene expression in PBMC shortly after vaccination. The occurrence of the type I IFN response in patients will be compared between the arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>immunogenicity - response to KLH</measure>
    <time_frame>up to 1.5 years</time_frame>
    <description>Proliferative, effector cytokine and humoral responses to keyhole limpet hemocyanin (KLH).The occurrence of the response will be compared between the arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>immunogenicity - T cells in DTH</measure>
    <time_frame>up to 1.5 years</time_frame>
    <description>Functional response and tetramer analysis of DTH infiltrating T cells against tumor peptides. The occurrence of the response will be compared between the arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>biodistribution/localization of pDC and myDC in the lymph node</measure>
    <time_frame>within 1 week after vaccination 1</time_frame>
    <description>biodistribution/localization of the injected labeled pDC and/or myDC in the resected lymph node by multiple techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety - Toxicity will be assessed according to the NCI Common Toxicity Criteria, CTC version 4.0</measure>
    <time_frame>up to 1.5 years</time_frame>
    <description>Toxicity will be assessed according to the NCI Common Toxicity Criteria, CTC version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>up to 5 years</time_frame>
    <description>To assess the quality of life the EORTC QLQ-C30 questionnaire will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>time from radical lymph node dissection to recurrence of (distant) disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>time from radical lymph node dissection to death</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>A: myDC vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranodal injection with tumor peptide-loaded myeloid dendritic cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: pDC vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranodal injection with tumor peptide-loaded plasmacytoid dendritic cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: combined myDC/pDC vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranodal injection with tumor peptide-loaded myeloid and plasmacytoid dendritic cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A: myDC vaccination</intervention_name>
    <arm_group_label>A: myDC vaccination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B: pDC vaccination</intervention_name>
    <arm_group_label>B: pDC vaccination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C: combined myDC/pDC vaccination</intervention_name>
    <arm_group_label>C: combined myDC/pDC vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stage III melanoma

          -  WHO performance status 0-1

          -  radical lymph node dissection is schedule or performed within 12 weeks prior to start
             of study treatment

        Exclusion Criteria:

          -  irresectable disease

          -  any concurrent adjuvant therapy

          -  concomitant use of oral immunosuppressive drugs

          -  autoimmune diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winald Gerritsen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

